Key Drivers
- Very high margins
- Strong liquidity
- Minimal debt
AIAI Summary
United Therapeutics has shifted from a single-product, binary biotech into a cash-generative, multi-franchise specialty pharma where near-term catalysts (IPF inhaled Tyvaso confirmatory data and ralinepag launch) can validate a buyback-fueled EPS re-rating, but the investment hinges on timely Phase‑III/filing wins, rapid payer uptake, and disciplined buyback vs. launch funding — monitor confirmatory trial readouts, early commercial uptake metrics, and buyback cadence as the decisive execution signals.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high margins
- •Strong liquidity
- •Minimal debt
UTHR is a highly profitable, capital‑light company with exceptional liquidity and cash generation but trades at a premium and faced sizable FY2025 investing/financing outflows.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Tight resistance
- •Volatile reversals
UTHR has rallied over the last month (~+10.8% from $473.42 to $524.28), showing higher lows and positive momentum but faces near-term resistance at ~$544.7 and would lose its short-term uptrend on a decisive break below $473–$486.
Sharp rise into early
Sentiment & News
Key News Insights:
- •Record revenue
- •$2B buyback
- •Clinical catalysts
United Therapeutics reported record FY2025 revenue and a Q4 EPS beat, unveiled a $2.0B buyback (with $1.5B ASR) and highlighted clinical catalysts that helped send the stock sharply higher.
Strong results, cash returns and advancing clinical data should sustain analyst optimism and shareholder support, likely keeping upward pressure on the stock in the near term
Similar Companies in Healthcare
Other companies in the same sector with AI ratings